Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Switching from weight-loss injections to Novo Nordisk's oral Wegovy pill doesn't stall progress — it may actually help. A real-world study of 194 patients found an average 4.1% body weight loss over just three months after making the switch. The findings, presented at a major diabetes conference in Milan, add clinical credibility to the growing case for oral obesity therapies.
Patients who transitioned from injectable GLP-1 obesity drugs — including Wegovy and Lilly's Zepbound — to Novo Nordisk's daily oral semaglutide pill continued to shed pounds, according to new real-world data presented at the European Association for the Study of Diabetes meeting in Milan. The 194-patient study, conducted in collaboration with U.S. telehealth company Ro, found that participants lost an average of 4.1% of their body weight over three months after switching to the pill.
The results are a boost for Novo as it battles to defend its lead in the fast-growing oral obesity market. Oral therapies now account for roughly a third of U.S. obesity prescriptions, with Novo capturing over 80% of new oral scripts. Novo's CEO has predicted pills could claim up to 50% of the global obesity drug market — projected to exceed $100 billion annually — by 2030.
By the Numbers
Why it matters: For clinicians and patients hesitant about switching from injections to pills, this real-world data suggests the transition doesn't mean sacrificing results — and for many, it may mean better adherence and continued weight loss.
